PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells

Blood

Volumn 121, Issue 6, 2013, Pages 962-970

  Yuki, Hiromichi ^a   Ueno, Shikiko ^a   Tatetsu, Hiro ^a   Niiro, Hiroaki ^b   Iino, Tadafumi ^b   Endo, Shinya ^a   Kawano, Yawara ^a   Komohara, Yoshihiro ^a   Takeya, Motohiro ^a   Hata, Hiroyuki ^a   Okada, Seiji ^c   Watanabe, Toshiki ^d   Akashi, Koichi ^b   Mitsuya, Hiroaki ^a   Okuno, Yutaka ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P21; PU.1 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SIZE; CELL CYCLE ARREST; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

EID: 84873604570     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-431429     Document Type: Article

References (43)

1. Chan J, Jaffe E, Ralfkiaer E, Ko Y. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Ed. Lyon, France: IARC Press; 2008.
2. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012;366(5):399-408.
3. von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 Trial. J Clin Oncol. 2012;30(9):907-913.
4. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203-212.
5. Chisesi T, Bellei M, Luminari S, et al. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/ CAD in patients with newly diagnosed advancedstage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. J Clin Oncol. 2011; 29(32):4227-4233.
6. Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011;29(32):4234-4242.
7. Halbsguth T, Nogova L, Mueller H, et al. Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2010;116(12):2026-2032.
8. Eich H, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199-4206.
9. Engert A, Diehl V, Franklin J, et al. Escalateddose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548-4554.
10. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010; 363(7):640-652.
11. van der Kaaij MA, Heutte N, Meijnders P, et al. Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study. J Clin Oncol. 2012;30(3):291-299.
12. Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol. 2011;29(31):4096-4104.
13. Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature. 2009; 459(7247):712-716.
14. Jundt F, Kley K, Anagnostopoulos I, et al. Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood. 2002;99(8):3060-3062. (Pubitemid 34525400)
15. McCune R, Syrbu S, Vasef M. Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB. 1, and PU.1 in Hodgkin's and non-Hodgkin's lymphomas: a comparative study using high throughput tissue microarrays. Mod Pathol. 2006; 19(7):1010-1018.
16. Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science. 1994;265(5178):1573-1577.
17. McKercher SR, Torbett BE, Anderson KL, et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J. 1996;15(20):5647-5658. (Pubitemid 26385624)
18. Li Y, Okuno Y, Zhang P, et al. Regulation of the PU.1 gene by distal elements. Blood. 2001; 98(10):2958-2965.
19. Okuno Y, Huang G, Rosenbauer F, et al. Potential autoregulation of transcription factor PU.1 by an upstream regulatory element. Mol Cell Biol. 2005; 25(7):2832-2845. (Pubitemid 40381644)
20. Tatetsu H, Ueno S, Hata H, et al. Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. Cancer Res. 2007;67(11):5328-5336. (Pubitemid 46997272)
21. Rosenbauer F, Wagner K, Kutok JL, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet. 2004;36(6):624-630. (Pubitemid 38715991)
22. Rosenbauer F, Owens BM, Yu L, et al. Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nat Genet. 2006;38(1):27-37. (Pubitemid 43011879)
23. Ushmorov A, Leithauser F, Sakk O, et al. Epigenetic processes play a major role in B-cellspecific gene silencing in classical Hodgkin lymphoma. Blood. 2006;107(6):2493-2500. (Pubitemid 43345573)
24. Era T, Witte ON. Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. Proc Natl Acad Sci U S A. 2000;97(4):1737-1742. (Pubitemid 30118512)
25. Miyoshi H, Takahashi M, Gage FH, Verma IM. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci U S A. 1997;94(19):10319-10323. (Pubitemid 27407039)
26. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol. 1998;72(10):8150-8157.
27. Ueno S, Tatetsu H, Hata H, et al. PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL. Oncogene. 2009;28(46): 4116-4125.
28. Dolbeare F, Gratzner H, Pallavicini MG, Gray JW. Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc Natl Acad Sci U S A. 1983;80(18):5573-5577.
29. Peterson KR, Clegg CH, Huxley C, et al. Transgenic mice containing a 248-kb yeast artificial chromosome carrying the human beta-globin locus display proper developmental control of human globin genes. Proc Natl Acad Sci U S A. 1993;90(16):7593-7597. (Pubitemid 23249996)
30. Kaufman RM, Pham CT, Ley TJ. Transgenic analysis of a 100-kb human beta-globin clustercontaining DNA fragment propagated as a bacterial artificial chromosome. Blood. 1999;94(9): 3178-3184. (Pubitemid 29512726)
31. Tanimoto K, Liu Q, Bungert J, Engel JD. Effects of altered gene order or orientation of the locus control region on human beta-globin gene expression in mice. Nature. 1999;398(6725):344-348.
32. Yu W, Misulovin Z, Suh H, et al. Coordinate regulation of RAG1 and RAG2 by cell type-specific DNA elements 5′ of RAG2. Science. 1999; 285(5430):1080-1084.
33. Loots GG, Locksley RM, Blankespoor CM, et al. Identification of a coordinate regulator of interleukins 4, 13, and 5 by cross-species sequence comparisons. Science. 2000;288(5463):136-140. (Pubitemid 30203046)
34. Okuno Y, Iwasaki H, Huettner CS, et al. Differential regulation of the human and murine CD34 genes in hematopoietic stem cells. Proc Natl Acad Sci U S A. 2002;99(9):6246-6251. (Pubitemid 34493297)
35. Okuno Y, Huettner CS, Radomska HS, et al. Distal elements are critical for human CD34 expression in vivo. Blood. 2002;100(13):4420-4426. (Pubitemid 35429680)
36. Radomska HS, Gonzalez DA, Okuno Y, et al. Transgenic targeting with regulatory elements of the human CD34 gene. Blood. 2002;100(13): 4410-4419. (Pubitemid 35429679)
37. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009;9(1):15-27.
38. Cabannes E, Khan G, Aillet F, Jarrett R, Hay R. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene. 1999;18(20):3063-3070. (Pubitemid 29261226)
39. Emmerich F, Meiser M, Hummel M, et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood. 1999;94(9):3129-3134. (Pubitemid 29512720)
40. Jungnickel B, Staratschek-Jox A, Brauninger A, et al. Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med. 2000;191(2):395-402.
41. Barth T, Martin-Subero J, Joos S, et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood. 2003;101(9): 3681-3686. (Pubitemid 36857959)
42. Joos S, Menz C, Wrobel G, et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood. 2002;99(4):1381-1387. (Pubitemid 34547095)
43. Martin-Subero J, Gesk S, Harder L, et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood. 2002;99(4): 1474-1477. (Pubitemid 34547107)